JP2009544756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544756A5 JP2009544756A5 JP2009522952A JP2009522952A JP2009544756A5 JP 2009544756 A5 JP2009544756 A5 JP 2009544756A5 JP 2009522952 A JP2009522952 A JP 2009522952A JP 2009522952 A JP2009522952 A JP 2009522952A JP 2009544756 A5 JP2009544756 A5 JP 2009544756A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- disease
- oxo
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC*C(CCC1N(CC[C@@]2*)C2=O)(C[C@]1N=C=O)O*CC* Chemical compound CCC*C(CCC1N(CC[C@@]2*)C2=O)(C[C@]1N=C=O)O*CC* 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83423506P | 2006-07-28 | 2006-07-28 | |
| US60/834,235 | 2006-07-28 | ||
| US89602607P | 2007-03-21 | 2007-03-21 | |
| US60/896,026 | 2007-03-21 | ||
| US11/782,742 US7629351B2 (en) | 2006-07-28 | 2007-07-25 | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US11/782,742 | 2007-07-25 | ||
| PCT/US2007/074377 WO2008014360A2 (en) | 2006-07-28 | 2007-07-26 | Modulators of chemokine receptor activity, crystalline forms and process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544756A JP2009544756A (ja) | 2009-12-17 |
| JP2009544756A5 true JP2009544756A5 (https=) | 2010-08-12 |
| JP5236643B2 JP5236643B2 (ja) | 2013-07-17 |
Family
ID=38829183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522952A Expired - Fee Related JP5236643B2 (ja) | 2006-07-28 | 2007-07-26 | ケモカイン受容体活性のモジュレーター、結晶形および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7629351B2 (https=) |
| EP (2) | EP2046779B1 (https=) |
| JP (1) | JP5236643B2 (https=) |
| KR (1) | KR20090033915A (https=) |
| CN (1) | CN101535301B (https=) |
| AR (1) | AR062124A1 (https=) |
| AT (2) | ATE522522T1 (https=) |
| AU (1) | AU2007279333B2 (https=) |
| BR (1) | BRPI0715415A2 (https=) |
| CA (2) | CA2831219A1 (https=) |
| CY (1) | CY1111744T1 (https=) |
| DK (1) | DK2046779T3 (https=) |
| EA (1) | EA016563B1 (https=) |
| ES (1) | ES2365264T3 (https=) |
| HR (1) | HRP20110465T1 (https=) |
| IL (2) | IL196427A (https=) |
| MX (1) | MX2009000808A (https=) |
| NO (1) | NO20090190L (https=) |
| NZ (1) | NZ574425A (https=) |
| PE (1) | PE20080732A1 (https=) |
| PL (1) | PL2046779T3 (https=) |
| PT (1) | PT2046779E (https=) |
| SG (1) | SG158924A1 (https=) |
| SI (1) | SI2046779T1 (https=) |
| TW (2) | TWI421249B (https=) |
| WO (1) | WO2008014360A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| KR20120135716A (ko) * | 2011-06-07 | 2012-12-17 | 한미사이언스 주식회사 | 이중대칭 구조의 퀴나졸린 유도체 화합물 및 이의 용도 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| MX2017000580A (es) * | 2014-07-17 | 2017-09-01 | Santen Pharmaceutical Co Ltd | Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo. |
| SMT202200088T1 (it) * | 2017-07-20 | 2022-03-21 | Bristol Myers Squibb Co | Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide |
| CN115677728A (zh) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | 一种海鞘素类化合物中间体的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6383082A (ja) | 1986-09-26 | 1988-04-13 | Takeda Chem Ind Ltd | テトラヒドロフランカルボン酸誘導体の製造法 |
| CA2084800A1 (en) | 1991-12-16 | 1993-06-17 | Joseph P. Vacca | Hiv protease inhibitors with an internal lactam ring |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| PL342254A1 (en) | 1998-01-29 | 2001-06-04 | Aventis Pharm Prod Inc | Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound |
| US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
| WO2001017992A1 (en) | 1999-09-09 | 2001-03-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| CA2432908A1 (en) | 2000-12-20 | 2002-06-27 | Bristol-Myers Squibb Pharma Company | Diamines as modulators of chemokine receptor activity |
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AU2002249103A1 (en) | 2001-03-29 | 2002-10-15 | Topo Target Aps | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
| GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
| DE10135043A1 (de) | 2001-07-11 | 2003-01-30 | Bayer Cropscience Gmbh | Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren |
| US7087604B2 (en) | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| US6835841B2 (en) | 2002-09-13 | 2004-12-28 | Bristol-Myers Squibb Company | Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2004071449A2 (en) | 2003-02-12 | 2004-08-26 | Bristol-Myers Squibb Company | Lactams as modulators of chemokine receptor activity |
| US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
| US7351720B2 (en) | 2003-06-12 | 2008-04-01 | Bristol-Myers Squibb Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| TWI354664B (en) * | 2003-08-21 | 2011-12-21 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine rece |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7317019B2 (en) | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
| US7863317B2 (en) | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| US20050043392A1 (en) | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| CA2575612A1 (en) | 2004-07-30 | 2006-02-09 | Pfizer Products Inc. | Methods of treating ccr2 mediated diseases or disorders |
| US20060069123A1 (en) | 2004-09-28 | 2006-03-30 | Mingde Xia | Substituted dipiperidine CCR2 antagonists |
| US7687508B2 (en) * | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
-
2007
- 2007-07-25 US US11/782,742 patent/US7629351B2/en active Active
- 2007-07-26 PT PT07813363T patent/PT2046779E/pt unknown
- 2007-07-26 AT AT10001989T patent/ATE522522T1/de not_active IP Right Cessation
- 2007-07-26 TW TW096127304A patent/TWI421249B/zh not_active IP Right Cessation
- 2007-07-26 EP EP07813363A patent/EP2046779B1/en not_active Not-in-force
- 2007-07-26 WO PCT/US2007/074377 patent/WO2008014360A2/en not_active Ceased
- 2007-07-26 AU AU2007279333A patent/AU2007279333B2/en not_active Ceased
- 2007-07-26 EP EP10001989A patent/EP2194051B1/en not_active Not-in-force
- 2007-07-26 SG SG201000703-7A patent/SG158924A1/en unknown
- 2007-07-26 CA CA2831219A patent/CA2831219A1/en not_active Abandoned
- 2007-07-26 JP JP2009522952A patent/JP5236643B2/ja not_active Expired - Fee Related
- 2007-07-26 PE PE2007000980A patent/PE20080732A1/es not_active Application Discontinuation
- 2007-07-26 AT AT07813363T patent/ATE509926T1/de active
- 2007-07-26 ES ES07813363T patent/ES2365264T3/es active Active
- 2007-07-26 CN CN200780032859.9A patent/CN101535301B/zh not_active Expired - Fee Related
- 2007-07-26 DK DK07813363.4T patent/DK2046779T3/da active
- 2007-07-26 MX MX2009000808A patent/MX2009000808A/es active IP Right Grant
- 2007-07-26 TW TW102141345A patent/TW201414729A/zh unknown
- 2007-07-26 EA EA200900245A patent/EA016563B1/ru not_active IP Right Cessation
- 2007-07-26 SI SI200730680T patent/SI2046779T1/sl unknown
- 2007-07-26 BR BRPI0715415-1A patent/BRPI0715415A2/pt not_active IP Right Cessation
- 2007-07-26 CA CA002659253A patent/CA2659253A1/en not_active Abandoned
- 2007-07-26 KR KR1020097004311A patent/KR20090033915A/ko not_active Ceased
- 2007-07-26 PL PL07813363T patent/PL2046779T3/pl unknown
- 2007-07-26 HR HR20110465T patent/HRP20110465T1/hr unknown
- 2007-07-26 NZ NZ574425A patent/NZ574425A/en not_active IP Right Cessation
- 2007-07-27 AR ARP070103332A patent/AR062124A1/es not_active Application Discontinuation
-
2009
- 2009-01-11 IL IL196427A patent/IL196427A/en not_active IP Right Cessation
- 2009-01-13 NO NO20090190A patent/NO20090190L/no not_active Application Discontinuation
- 2009-10-27 US US12/606,255 patent/US8049019B2/en active Active
-
2010
- 2010-06-28 IL IL206679A patent/IL206679A0/en unknown
-
2011
- 2011-08-05 CY CY20111100753T patent/CY1111744T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544756A5 (https=) | ||
| JP5264830B2 (ja) | アミノクロトニル化合物の調製方法 | |
| JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| JP2009544758A5 (https=) | ||
| JP6832946B2 (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
| WO1998022432A1 (en) | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same | |
| CA2894016A1 (en) | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| JP2005514373A5 (https=) | ||
| JP2020534336A5 (https=) | ||
| JP2012513381A5 (https=) | ||
| IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
| JP6297590B2 (ja) | １−（［１，３］ジオキソラン−４−イルメチル）−１ｈ−ピラゾール−３−イルアミンを調製するための方法 | |
| CN1771234A (zh) | 吡咯并三嗪激酶抑制剂的制备方法 | |
| CN109476609B (zh) | 吡唑-酰胺化合物的制造方法 | |
| US10377712B2 (en) | Process for preparation of apremilast and novel polymorphs thereof | |
| JP2008544965A (ja) | ｐ３８キナーゼ阻害剤としての二環式誘導体 | |
| US20190144375A1 (en) | Novel carbocyclic compounds as ror gamma modulators | |
| KR101643285B1 (ko) | （하이드록시알킬）피롤 유도체의 회전장애이성질체 | |
| JP7406692B2 (ja) | 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法 | |
| JP2008539181A (ja) | Ｅｐ１受容体アンタゴニストとして有用なフラン化合物 | |
| JP2002501064A (ja) | 複素芳香環縮合シクロペンテノピリジン誘導体 | |
| WO2025215672A1 (en) | "process for preparation of blarcamesine" | |
| JP2005532362A (ja) | インドール誘導スタチンのカルシウム塩 | |
| JPH083162A (ja) | イミダゾピリジン誘導体及びその製法 |